HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNγ production by CD4+ T cells.

[1]  D. Alotto,et al.  Preparation and Characterization of a Novel Skin Substitute , 2010, Journal of biomedicine & biotechnology.

[2]  R. Sartorius,et al.  Triggering DTH and CTL Activity by fd Filamentous Bacteriophages: Role of CD4+ T Cells in Memory Responses , 2010, Journal of biomedicine & biotechnology.

[3]  R. Levy,et al.  Antigenic characteristics of rhinovirus chimeras designed in silico for enhanced presentation of HIV-1 gp41 epitopes [corrected]. , 2010, Journal of molecular biology.

[4]  M. Hoelscher,et al.  A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). , 2010, The Journal of infectious diseases.

[5]  Laurie Lamoreaux,et al.  Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses , 2010, PloS one.

[6]  M. Robb,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[7]  D. Burton,et al.  Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10 Directed against the Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Protect against Mucosal Challenge by Simian-Human Immunodeficiency Virus SHIVBa-L , 2009, Journal of Virology.

[8]  Sierin Lim,et al.  pH-triggered disassembly in a caged protein complex. , 2009, Biomacromolecules.

[9]  M. Betts,et al.  Adenovirus-Specific Immunity Following Immunization with an Ad5 HIV-1 Vaccine Candidate in Humans , 2009, Nature Medicine.

[10]  D. Burton,et al.  Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers , 2009, PLoS pathogens.

[11]  L. Picker,et al.  Effector-memory T cell responses are associated with protection of rhesus monkeys from mucosal SIV challenge , 2009, Nature Medicine.

[12]  C. Parish,et al.  Use of the Intracellular Fluorescent Dye CFSE to Monitor Lymphocyte Migration and Proliferation , 2009, Current protocols in immunology.

[13]  Devan V Mehrotra,et al.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.

[14]  Sierin Lim,et al.  Thermostability and molecular encapsulation within an engineered caged protein scaffold , 2008, Biotechnology and bioengineering.

[15]  S. Hammer,et al.  HIV Vaccine Research: The Way Forward , 2008, Science.

[16]  P. De Berardinis,et al.  Phage display of a CTL epitope elicits a long‐term in vivo cytotoxic response , 2007, FEMS immunology and medical microbiology.

[17]  D. Burton,et al.  Antigenic and Immunogenic Study of Membrane-Proximal External Region-Grafted gp120 Antigens by a DNA Prime-Protein Boost Immunization Strategy , 2007, Journal of Virology.

[18]  K. Mansfield,et al.  Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity , 2006, Nature.

[19]  D. Montefiori,et al.  Effect of CD8+ Lymphocyte Depletion on Virus Containment after Simian Immunodeficiency Virus SIVmac251 Challenge of Live Attenuated SIVmac239Δ3-Vaccinated Rhesus Macaques , 2005, Journal of Virology.

[20]  J. Mascola,et al.  Replication-Defective Adenovirus Serotype 5 Vectors Elicit Durable Cellular and Humoral Immune Responses in Nonhuman Primates , 2005, Journal of Virology.

[21]  R. Wagner,et al.  Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. , 2005, Molecular immunology.

[22]  N. Haigwood,et al.  New recombinant vaccines based on the use of prokaryotic antigen-display systems , 2004, Expert review of vaccines.

[23]  J. Lifson,et al.  Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. , 2004, AIDS Research and Human Retroviruses.

[24]  C. Ohlen,et al.  Multigene DNA Priming-Boosting Vaccines Protect Macaques from Acute CD4+-T-Cell Depletion after Simian-Human Immunodeficiency Virus SHIV89.6P Mucosal Challenge , 2003, Journal of Virology.

[25]  B. Autran,et al.  Yeast-Derived Human Immunodeficiency Virus Type 1 p55gag Virus-Like Particles Activate Dendritic Cells (DCs) and Induce Perforin Expression in Gag-Specific CD8+ T Cells by Cross-Presentation of DCs , 2003, Journal of Virology.

[26]  D. Piatier‐Tonneau,et al.  Use of fusion proteins and procaryotic display systems for delivery of HIV-1 antigens: development of novel vaccines for HIV-1 infection. , 2003, Current HIV research.

[27]  D. Piatier‐Tonneau,et al.  Induction of specific T-helper and cytolytic responses to epitopes displayed on a virus-like protein scaffold derived from the pyruvate dehydrogenase multienzyme complex. , 2003, Vaccine.

[28]  Yan Li,et al.  Budding and secretion of HIV Gag-Env virus-like particles from recombinant human adenovirus infected cells. , 2003, Virus research.

[29]  Jianping Ding,et al.  Crystal structure of a human rhinovirus that displays part of the HIV-1 V3 loop and induces neutralizing antibodies against HIV-1. , 2002, Structure.

[30]  B. M. Flynn,et al.  Role of CD8+ Lymphocytes in Control of Simian Immunodeficiency Virus Infection and Resistance to Rechallenge after Transient Early Antiretroviral Treatment , 2001, Journal of Virology.

[31]  R. Perham,et al.  Multiple display of peptides and proteins on a macromolecular scaffold derived from a multienzyme complex. , 2001, Journal of molecular biology.

[32]  R. Wagner,et al.  Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. , 2000, AIDS research and human retroviruses.

[33]  J. Mascola,et al.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.

[34]  Tahir A. Rizvi,et al.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.

[35]  N. Haigwood,et al.  Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys , 1999, Nature Medicine.

[36]  R. Perham,et al.  Expression of genes encoding the E2 and E3 components of the Bacillus stearothermophilus pyruvate dehydrogenase complex and the stoichiometry of subunit interaction in assembly in vitro. , 1998, European journal of biochemistry.

[37]  J. Lifson,et al.  Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. , 1998, AIDS research and human retroviruses.

[38]  M. Allen,et al.  The catalytic domain of dihydrolipoyl acetyltransferase from the pyruvate dehydrogenase multienzyme complex of Bacillus stearothermophilus , 1997, FEBS letters.

[39]  F. Lemonnier,et al.  HLA-A2.1–restricted Education and Cytolytic Activity of CD8+ T Lymphocytes from β2 Microglobulin (β2m) HLA-A2.1 Monochain Transgenic H-2Db β2m Double Knockout Mice , 1997, The Journal of experimental medicine.

[40]  K. Steimer,et al.  Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. , 1997, Vaccine.

[41]  J. Strominger,et al.  Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus , 1995, Journal of virology.

[42]  R. Webster,et al.  Design and construction of rhinovirus chimeras incorporating immunogens from polio, influenza, and human immunodeficiency viruses. , 1994, Virology.

[43]  J. Ledbetter,et al.  Inhibition of virus production in peripheral blood mononuclear cells from human immunodeficiency virus (HIV) type 1-seropositive donors by treatment with recombinant HIV-like particles , 1992, Journal of virology.

[44]  N. Haigwood,et al.  Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[45]  P. Matzinger.  The JAM test. A simple assay for DNA fragmentation and cell death. , 1991, Journal of immunological methods.

[46]  E. Stott,et al.  Anti-cell antibody in macaques , 1991, Nature.

[47]  O. Haffar,et al.  HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles. , 1991, Virology.

[48]  O. Haffar,et al.  Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system , 1990, Journal of virology.

[49]  J. Salk.  Prospects for the control of AIDS by immunizing seropositive individuals , 1987, Nature.

[50]  J. Finch,et al.  Structure and symmetry of B. stearothermophilus pyruvate dehydrogenase multienzyme complex and implications for eucaryote evolution , 1979, Cell.

[51]  Sierin Lim,et al.  Design of a pH-dependent molecular switch in a caged protein platform. , 2009, Nano letters.

[52]  R. Perham,et al.  Swinging arms and swinging domains in multifunctional enzymes: catalytic machines for multistep reactions. , 2000, Annual review of biochemistry.

[53]  R. Locksley,et al.  The regulation of immunity to Leishmania major. , 1995, Annual review of immunology.

[54]  R. Montelaro,et al.  A formalin inactivated whole SIV vaccine and a glycoprotein-enriched subunit vaccine confers protection against experimental challenge with pathogenic live SIV in rhesus monkeys. , 1990, Developments in biological standardization.